USE OF INPATIENT SYSTEMIC CHEMOTHERAPY AND/OR RADIOTHERAPY AND RELATED PREDICTIVE FACTORS FOR METASTATIC UROTHELIAL CANCER (MUC): FINDINGS FROM A RETROSPECTIVE OBSERVATIONAL STUDY IN A CLINICAL PRACTICE SETTING IN ITALY

被引：0
|
作者：
Kearney, M. [1 ]
Thompson, A. [2 ]
Kirker, M. [2 ]
Gharibian, N. [2 ,3 ]
Costa, N. [3 ]
Furegato, M. [4 ]
Pacheco, C. [4 ]
Issa, S. [4 ]
Sciattella, P. [5 ]
Scortichini, M. [5 ]
Mennini, F. S. [5 ]
机构：
[1] Merck Healthcare KGaA, Darmstadt, Germany
[2] Pfizer, New York, NY USA
[3] Pfizer, Porto Salvo, Portugal
[4] Cerner Enviza France SAS, Paris, France
[5] Univ Roma Tor Vergata, Fac Econ, DEF Dept, Econ Evaluat & HTA EEHTA CEIS, Rome, Italy
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO20
引用
收藏
页码：S17 / S18
页数：2
相关论文
共 17 条
  • [1] HEALTHCARE RESOURCE UTILIZATION (HCRU) AND RELATED DIRECT HEALTHCARE COSTS FOR PATIENTS WITH METASTATIC UROTHELIAL CANCER (MUC): FINDINGS FROM A RETROSPECTIVE OBSERVATIONAL COHORT STUDY IN A CLINICAL PRACTICE SETTING IN ITALY
    Kearney, M.
    Thompson, A.
    Kirker, M.
    Gharibian, N.
    Costa, N.
    Furegato, M.
    Pacheco, C.
    Issa, S.
    Sciattella, P.
    Scortichini, M.
    Mennini, F. S.
    VALUE IN HEALTH, 2023, 26 (12) : S154 - S154
  • [2] Use of inpatient systemic chemotherapy and/or radiotherapy and related predictive factors, healthcare resource utilization, and direct hospitalization costs for metastatic urothelial cancer: findings from a real-world retrospective observational study derived from the national hospital discharge claims database in Italy
    Kearney, Mairead
    Kirker, Melissa
    Thompson, Allison
    Gharibian, Norbek
    Furegato, Martina
    Pacheco, Cecile
    Issa, Seham
    Hasanova, Reyhan
    Sciattella, Paolo
    Scortichini, Matteo
    Mennini, Francesco Saverio
    BMC CANCER, 2024, 24 (01)
  • [3] Factors associated with not receiving systemic treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
    Niegisch, G.
    Kearney, M.
    Krieger, J.
    Osowski, U.
    Weinhold, C.
    Deiters, B.
    Maywald, U.
    Guenther, S.
    Wilke, T.
    Grimm, M-O.
    ANNALS OF ONCOLOGY, 2023, 34 : S1215 - S1215
  • [4] Factors associated with not receiving systemic anticancer treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): results of a retrospective observational study in Germany
    Niegisch, Guenter
    Kearney, Mairead
    Krieger, Julia
    Osowski, Ulrike
    Weinhold, Carina
    Deiters, Barthold
    Maywald, Ulf
    Guenther, Silke
    Wilke, Thomas
    Grimm, Marc-Oliver
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 84 - 84
  • [5] Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database
    Bamias, A.
    Tzannis, K.
    Liontos, M.
    Harshman, L.
    Crabb, S. J.
    Wong, Y-N.
    Pal, S. K.
    Powles, T. B.
    Bellmunt, J.
    De Giorgi, U.
    Ladoire, S.
    Agarwal, N.
    Yu, E. Y.
    Niegisch, G.
    Sternberg, C. N.
    Alva, A.
    Srinivas, S.
    Rosenberg, J.
    Investigators, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study
    Bamias, A.
    Merseburger, A.
    Loriot, Y.
    James, N.
    Choy, E.
    Gauna, D. Castellano
    Lopez-Rios, F.
    Calabro, F.
    Kramer, M. W.
    de Velasco, G.
    Zakopoulou, R.
    Tzannis, K.
    Sternberg, C. N.
    ANNALS OF ONCOLOGY, 2020, 31 : S581 - S581
  • [7] Split-dose cisplatin plus gemcitabine use and associated clinical outcomes in the first-line (1L) treatment of locally advanced or metastatic urothelial cancer (la/mUC): Results of a retrospective observational study in Germany (CONVINCE)
    Schlack, K.
    Kubin, T.
    Ruhnke, M.
    Schulte, C.
    Machtens, S.
    Eisen, A.
    Osowski, U.
    Guenther, S.
    Kearney, M.
    Lipp, R.
    Schmitz, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1216 - S1216
  • [8] Clinical characteristics and prognostic factors among hospitalized patients with substance use disorders: Findings from a retrospective cohort study of a Canadian inpatient addiction medicine service
    Martin, Leslie J.
    Bawor, Monica
    Bains, Supriya
    Burns, Jacinda
    Khoshroo, Saba
    Massey, Myra
    DeJesus, Jane
    Lennox, Robin
    Cook-Chaimowitz, Lauren
    OShea, Tim
    MacKillop, James
    Dennis, Brittany B.
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 157
  • [9] Split-dose cisplatin (C) plus gemcitabine (G) use and associated clinical outcomes in the first-line (1L) treatment (tx) of locally advanced or metastatic urothelial cancer (la/mUC): results of a retrospective observational study in Germany (CONVINCE)
    Schlack, Katrin
    Kubin, Thomas W.
    Ruhnke, Markus
    Schulte, Clemens
    Machtens, Stefan
    Eisen, Anna
    Osowski, Ulrike
    Guenther, Silke
    Kearney, Mairead
    Lipp, Rainer
    Schmitz, Stephan
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 83 - 83
  • [10] The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand
    Sirikul, Wachiranun
    Buawangpong, Nida
    Pruksakorn, Dumnoensun
    Charoentum, Chaiyut
    Teeyakasem, Pimpisa
    Koonrungsesomboon, Nut
    CANCERS, 2023, 15 (07)
12